| "A 25-year-old pregnant women with cryptococcal meningitis treated with itraconazole during the first few weeks and 12th-16th week of pregnancy is reported." | ( Chotmongkol, V; Sookprasert, A, 1992) |
| "After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse." | ( Cloud, GA; Follansbee, SE; Graybill, JR; Jacobson, JM; McAuliffe, VJ; Meyer, RD; Powderly, WG; Robinson, P; Saag, MS; Sugar, AM, 1992) |
| "Treatment of cryptococcal meningitis in patients with AIDS with amphotericin B plus flucytosine is associated with a failure rate of 20%-30%." | ( Powderly, WG, 1992) |
| "Two of three patients with acute cryptococcal meningitis completed the 12-week primary therapy, and one patient was discontinued from therapy because of a skin rash (95% confidence interval, 14-100%)." | ( Chambers, HF; Lee, BL; Padula, AM; Sande, MA; Täuber, MG, 1992) |
| "Three patients with AIDS who had cryptococcal meningitis were treated with liposomal amphotericin B after unsuccessful treatment with fluconazole and conventional amphotericin B." | ( Coker, RJ; Harris, JR; Murphy, SM, 1991) |
| "Treatment of cryptococcal meningitis with amphotericin B or fluconazole is often unsuccessful; in only 35%-40% of cases do CSF cultures become negative by 10 weeks after initiation of such therapy." | ( Bauer, M; Bozzette, SA; Forthal, D; Haghighat, D; Jones, BE; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Tilles, JG, 1994) |
| "Four patients with cryptococcal meningitis have been treated with fluconazole in the past two years at the Department of Neurology, National Cheng Kung University Medical Center." | ( La, ML; Ong, CT; Tsai, JJ, 1993) |
| "Treatment of cryptococcal meningitis was successful in 17 of the 19 patients given fluconazole but only three of the six receiving itraconazole." | ( Cartledge, J; Fisher, M; Gazzard, BG; Nelson, MR; Rogers, T, 1994) |
| "We report a case of cryptococcal meningitis in a 31-year-old HIV-positive man which was successfully treated with amphotericin B lipid emulsion." | ( Appleyard, MN; Hartley, JP; Leake, HA, 1994) |
| "After he was diagnosed as cryptococcal meningitis using the microscopy, cryptococcal antigen detection and culture of cerebrospinal fluid, treatment with amphotericin-B and fluconazole was started." | ( Imae, N; Konishi, M; Maeda, K; Masutani, T; Migita, T; Mikasa, K; Mori, K; Narita, N; Sano, R; Sawaki, M; Yamanaka, T; Yoshioka, A, 1996) |
| "To describe a patient with cryptococcal meningitis treated with the combination of amphotericin B and fluconazole." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "A 41-year-old woman with cryptococcal meningitis who was not infected with HIV was treated with a combination of amphotericin B and fluconazole because she did not respond to amphotericin B alone and could not tolerate amphotericin B with flucytosine." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "Standard therapy for cryptococcal meningitis is amphotericin B with or without flucytosine." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "A patient with cryptococcal meningitis was treated with the combination of amphotericin B and fluconazole because of a poor response to amphotericin B monotherapy and intolerance to flucytosine." | ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "HIV-infected patients with cryptococcal meningitis were randomized to treatment with either liposomal amphotericin B (AmBisome) 4 mg/kg daily or standard amphotericin B 0." | ( Allworth, T; Borleffs, JC; Clezy, K; de Marie, S; Hop, WC; Hoy, J; Jones, P; Kauffmann, RH; Kroon, FP; Leenders, AC; Portegies, P; Reiss, P; Verbrugh, HA, 1997) |
| "Four patients with cryptococcal meningitis were successfully treated with liposomal amphotericin B prepared at our institute using Soya phosphatidylcholine and cholesterol." | ( Bodhe, PV; Gokhale, PC; Kirodian, BG; Kotwani, RN; Kshirsagar, NA, 2001) |
| "4 months later he was admitted with cryptococcal meningitis and was treated successfully with amphotericin B." | ( Elias, M; Flatau, E; Raz, R; Reichman, N, 1999) |
| "Nine cases of cryptococcal meningitis or menigoencephalitis treated with Ambisome were clinically cured with an effective rate of 100%, within a mean course of 50 days, which was shorter than that of C-Amb, by a mean cumulative dose of 1807." | ( Hai, W; Wanqing, L; Wei, H, 2003) |
| "HIV infected patients with primary cryptococcal meningitis, who had been treated initially with amphotericin B for 2 weeks were included in this study." | ( Anunnatsiri, S; Chetchotisakd, P; Choksawadphinyo, K; Mootsikapun, P, 2003) |
| "Forty Thai patients with AIDS and cryptococcal meningitis, of whom 20 had been receiving oral rifampicin for at least 2 weeks to treat tuberculosis." | ( Panomvana Na Ayudhya, D; Tansuphaswadikul, S; Thanompuangseree, N, 2004) |
| "Patients were treated for cryptococcal meningitis with amphotericin 0." | ( Panomvana Na Ayudhya, D; Tansuphaswadikul, S; Thanompuangseree, N, 2004) |
| "Despite evidence of unresolved cryptococcal meningitis, each patient underwent implantation of a VP shunt without complication and was discharged on lifetime fluconazole therapy." | ( McGirt, MJ; Rigamonti, D; Williams, MA; Woodworth, GF, 2005) |
| "We report two patients with cryptococcal meningitis and combined immunodeficiency with unusual magnetic resonance imaging findings of gadolinium-enhancing white matter lesions, quite different from cryptococcomas and seen prior to anti-fungal treatment." | ( Kempster, P; Thyagarajan, D; Wilcox, RA, 2007) |
| "In 2000, cryptococcal meningitis was a common HIV related opportunistic infection in central Thailand requiring inpatient management but few patients suffering from it could afford a full course of treatment once infection had occurred." | ( Inverarity, D; Wright, P, 2007) |
| "Patients with cryptococcal meningitis clearly benefit from early fungicidal therapy but require long-term suppression." | ( Graybill, JR; Lewis, JS, 2008) |
| "An all oral treatment for cryptococcal meningitis is attractive, particularly where amphotericin B use is impractical." | ( Bozzette, SA; Haubrich, R; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Milefchik, E; Tilles, JG, 2008) |
| "Two HIV-infected patients had recurrent cryptococcal meningitis (CM) despite treatment with fluconazole and immune reconstitution with combination antiretroviral therapy (CART)." | ( Corbett, EL; Ferrand, RA; Mangeya, N; Miller, RF; Seddon, J, 2009) |
| "Considering cryptococcal meningitis in that context, this review addresses excess morbidity and mortality in developing countries, treatment in areas of limited drug availability and challenges posed by combined anticryptococcal and HIV therapy." | ( Dedicoat, MJ; Lalloo, DG; Sloan, DJ, 2009) |
| "Progress in therapy for cryptococcal meningitis has been slow because of the lack of a suitable marker of treatment response." | ( Bekker, LG; Bicanic, T; Brouwer, AE; Chierakul, W; Harrison, TS; Jaffar, S; Jarvis, J; Limmathurotsakul, D; Longley, N; Loyse, A; Meintjes, G; Muzoora, C; Rebe, K; Stepniewska, K; Taseera, K; White, NJ; Wood, R, 2009) |
| "Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS." | ( Anekthananon, T; Chetchotisakd, P; Filler, SG; Johnson, PC; Kendrick, AS; Kopetskie, H; Larsen, RA; Manosuthi, W; Morris, MI; Nolen, TL; Pappas, PG; Sobel, JD; Sungkanuparph, S; Supparatpinyo, K, 2009) |
| "We provided pharmaceutical care for a cryptococcal meningitis case to study the role that clinical pharmacists played in clinical pharmacotherapy." | ( Li, CX; Liu, F; Zhai, SD; Zhang, XY, 2009) |
| "We present a case of relapsing cryptococcal meningitis unresponsive to standard therapy." | ( Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR, 2010) |
| "We report two children who had cryptococcal meningitis and associated increased intracranial pressure, and were treated with an Ommaya reservoir." | ( Gao, F; Jiang, PF; Shen, SX; Shui, QX; Xia, ZZ; Yu, HM; Zhou, BL, 2010) |
| "In non-AIDS patients with cryptococcal meningitis admitted to Huashan Hospital, Fudan University in Shanghai from January 1998 to December 2007, 31 were initially treated with low-dose amphotericin B and flucytosine for more than 1 week." | ( Huang, YX; Jiang, WM; Jin, JL; Ou, XT; Weng, XH; Wu, JQ; Xie, Y; Xu, B; Zhu, LP, 2010) |
| "A patient with cryptococcal meningitis and SLE, who responded well to amphotericin deoxycholate therapy, is reported." | ( Tristano, AG, 2010) |
| "Mortality related to cryptococcal meningitis remains high, and novel treatment strategies are needed." | ( Bekker, LG; Bicanic, T; Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Schutz, C; Williams, A; Williams, GN; Wood, R, 2012) |
| "We present 2 cases of HIV-related cryptococcal meningitis, persisting after 3 and 9 months, respectively, of standard treatment." | ( Gamaletsou, MN; Kontos, AN; Kontoyiannis, DP; Kordossis, T; Sipsas, NV; Stefanou, I; Tsiakalos, A, 2012) |
| "Of 46 patients with cryptococcal meningitis identified, 21 were cured after 10 weeks of treatment." | ( Chang, TY; Chen, FJ; Chien, CC; Lee, CH; Liu, JW; Lu, CH; Tang, YF, 2012) |
| "The patient with cryptococcal meningitis was treated with amphotericin B and fluconazole and the patient with cerebral aspergilloma with voriconazole." | ( Baršić, B; Mlinarić Missoni, E, 2012) |
| "Mortality and treatment failure from cryptococcal meningitis following initiation of treatment with 800 mg oral fluconazole is unacceptably high." | ( Allain, T; Chikafa, J; Denis, B; Feasey, NA; Goodson, P; Harrison, T; Heyderman, RS; Lalloo, DG; Mukaka, M; Rothe, C; Sloan, DJ; van Oosterhout, JJ, 2013) |
| "We present a case of cryptococcal meningitis in a renal transplant recipient presenting as acute sinusitis with successful treatment using fluconazole as primary therapy." | ( Alangaden, G; Carron, M; Chandrasekar, P; Iyer, SP; Movva, K; Revankar, SG; Tranchida, P; Wiebel, M, 2013) |
| "For the first time, we report a case of cryptococcal meningitis during the treatment of chronic HCV with PEG-interferon-α and ribavirin." | ( Choi, YW; Huh, KC; Kang, YW; Kim, SM; Kim, YS; Lee, KO; Lee, TH, 2014) |
| "She was diagnosed with cryptococcal meningitis and treated with antifungal therapy." | ( Almeida, AC; Costa, JM; Passarinho, MP; Portelinha, J, 2014) |
| "For persons with symptomatic cryptococcal meningitis, optimal initial management with amphotericin and flucytosine improves survival compared to alternative therapies; however, amphotsericin is difficult to administer and flucytosine has not been available in middle or low income countries, where cryptococcal meningitis is most prevalent." | ( Abassi, M; Boulware, DR; Lofgren, S; Rhein, J, 2017) |
| "Eighteen out of 26 cryptococcal meningitis patients were treated with amphotericin B (AmB)-based therapy, 16 of them with AmB deoxycholate (d-AmB) and 2 patients with liposomal AmB." | ( Cao, YH; Chen, YQ; Wang, RY; Wang, X; Wu, JQ; Zhao, HZ; Zhu, LP, 2017) |
| "Under-diagnosed cryptococcal meningitis following VP shunt insertion for treating the hydrocephalus can render a complicated VP shunt infection including infected VP shunt pseudocyst." | ( Chongtrakool, P; Dhitinanmuang, W; Jitmuang, A, 2018) |
| "Annual global deaths from cryptococcal meningitis (CM) are estimated at 180 000 and mortality is as high as 30%, even with optimal therapy." | ( Garvey, EP; Schotzinger, RJ; Sharp, AD; Warn, PA; Yates, CM, 2018) |
| "Two trials treated cryptococcal meningitis with amphotericin B and fluconazole; a third trial used fluconazole monotherapy; and the fourth trial did not specify the antifungal used." | ( Bicanic, T; Eshun-Wilson, I; Okwen, MP; Richardson, M, 2018) |
| "A diagnosis of cryptococcal meningitis was made and the patient was started on 1200 mg fluconazole once daily and flucytosine 25 mg/kg four times daily as part of the Advancing Cryptococcal Treatment for Africa (ACTA) clinical trial." | ( Benjamin, LA; Ellis, JP; Harrison, TS; Heyderman, RS; Joekes, EC; Kalata, N; Kampondeni, S; Lalloo, DG, 2018) |
| "We present the first case of cryptococcal meningitis in a patient who was being administered everolimus for breast cancer." | ( Nakamura, T; Sato, H; Seki, S; Takase, K; Yamamoto, T; Yoshida, T, 2018) |
| "She was diagnosed with cryptococcal meningitis in diabetes and had a remarkable response to fluconazole monotherapy." | ( Chege, P; Owuor, OH, 2019) |
| "Clinical treatment of cryptococcal meningitis (CM) remains a significant challenge because of the lack of effective and safe drug therapies." | ( Han, G; Ji, C; Jiang, Y; Li, Z; Liu, N; Sheng, C; Tu, J; Wang, Y, 2019) |
| "The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made." | ( Alanio, A; Boyer-Chammard, T; Harrison, TS; Jarvis, JN; Lortholary, O; Temfack, E, 2019) |
| "Management of co-infections including cryptococcal meningitis, tuberculosis and other opportunistic infections in persons living with HIV can lead to complex polypharmacotherapy and increased susceptibility to drug-drug interactions (DDIs)." | ( Boulware, DR; Eneh, PC; Hullsiek, KH; Kiiza, D; Meya, DB; Nicol, MR; Rhein, J, 2020) |
| "Treatment of life-threatening cryptococcal meningitis (CM) is highly challenging due to the limited efficacy of the available antifungal drugs." | ( Ji, C; Li, J; Li, W; Liu, N; Sheng, C; Tu, J; Yang, W; Yun, Z, 2022) |
| "Albeit fingolimod associated cryptococcal meningitis is a rare event, Fingolimod therapy in patients with MS should be performed cautiously." | ( Darazam, IA; Gharehbagh, FJ; Hatami, F; Lotfollahi, L; Moradi, O; Nourinia, R; Rabiei, MM; Roozbeh, M; Shojaei, M, 2022) |